Q-omics provides the consensus-scored BBS7 profile across patient tissues and cancer cell-line models. BBS7 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BBS7 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, BBS7 protein abundance shows 21,382 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, THCA, and BRCA as cancer lineages where BBS7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BBS7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BBS7 survival associations across molecular data types. BBS7 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BBS7 RNA expression–survival associations across cancer types. High BBS7 expression shows unfavorable associations in KICH, LIHC, LGG and CESC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BBS7 RNA expression.
This table summarizes BBS7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BBS7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BBS7 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher BBS7 RNA expression in normal versus tumor tissue (log2 FC = −0.591, t-test p < 0.001).
This table shows molecular features associated with BBS7 in patient tissues and cancer cell lines. In patient samples, BBS7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BBS7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
